Vaxcyte (PCVX) Competitors

Intra-Cellular Therapies (NASDAQ:ITCI) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Which has higher earnings and valuation, ITCI or PCVX?

Intra-Cellular Therapies has higher revenue and earnings than Vaxcyte. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intra-Cellular Therapies	$680.50M	20.64	-$139.67M	-$0.73	-180.64
Vaxcyte	N/A	N/A	-$402.27M	-$3.99	-9.17

Does the MarketBeat Community favor ITCI or PCVX?

Intra-Cellular Therapies received 467 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote.

Company	Underperform	Outperform
Intra-Cellular Therapies	Outperform Votes 522 65.74%	Underperform Votes 272 34.26%
Vaxcyte	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%

Is ITCI or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intra-Cellular Therapies	-14.07%	-9.93%	-8.38%
Vaxcyte	N/A	-23.53%	-22.20%

Do analysts rate ITCI or PCVX?

Intra-Cellular Therapies presently has a consensus target price of $109.70, indicating a potential downside of 16.81%. Vaxcyte has a consensus target price of $136.50, indicating a potential upside of 273.26%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Intra-Cellular Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intra-Cellular Therapies	0 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10

Which has more risk & volatility, ITCI or PCVX?

Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Does the media refer more to ITCI or PCVX?

In the previous week, Vaxcyte had 13 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 16 mentions for Vaxcyte and 3 mentions for Intra-Cellular Therapies. Vaxcyte's average media sentiment score of 1.32 beat Intra-Cellular Therapies' score of 0.25 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intra-Cellular Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in ITCI or PCVX?

92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Vaxcyte beats Intra-Cellular Therapies on 12 of the 18 factors compared between the two stocks.